November 12, 2025 – CannabisReporter.news – Aurora Cannabis Inc. (TSX: ACB) reported a decisive swing toward profitability in its latest quarterly update, underscoring the strength of its global medical cannabis operations. Net revenue climbed 15 per cent year-over-year, driven by robust demand in Germany, Poland and Australia. Adjusted EBITDA surged 52 per cent, marking Aurora’s most profitable quarter since its restructuring began.
The company’s gross margin expanded to 61 per cent, reflecting disciplined cost control and the higher-value profile of medical cannabis exports. Aurora confirmed its EU-GMP recertification and announced expansion at its Leuna facility, positioning itself among the few Canadian producers with scalable international reach.
Management emphasized that free cash flow is expected to turn positive in the fiscal third quarter ending December, supported by C$142 million in cash reserves and zero cannabis-related debt. Aurora’s balance sheet strength has drawn investor attention, with shares trading at 0.9 times forward sales, a discount to peers.
The company’s pivot away from domestic recreational sales toward international medical markets is resonating with analysts, who cite Aurora’s disciplined capital allocation and regulatory expertise as differentiators. With Canada’s cannabis sector facing pricing pressure and oversupply, Aurora’s global medical footprint offers a pathway to sustainable growth.
Aurora’s leadership reaffirmed its commitment to profitability, noting that international medical cannabis remains the industry’s most compelling growth area. Investors are watching closely as Aurora positions itself as Canada’s flagship exporter in a consolidating global market.
